| Date | Title | Description |
| 23.03.2026 | Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss | Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial.
Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited “strong efficacy” for its ... |
| 25.08.2025 | US suspends chikungunya vaccine Ixchiq over 'serious' side effects: Valneva | PARIS: US health authorities have suspended the licence for the Ixchiq vaccine against the chikungunya virus following reports of "serious adverse events", the drug's French maker said on Monday (Aug 25).
Ixchiq is one of just two... |
| 09.06.2025 | No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says | No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says
By Michael ErmanJune 9, 20253:52 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Pfizer logo is seen in this ... |
| 04.06.2025 | Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction | Saint-Herblain (France), le 4 juin 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des documents préparatoires à son Assemblée Géné... |
| 18.04.2025 | Valneva fait le point sur la recommandation de l'ACIP pour les voyageurs américains concernant son vaccin IXCHIQ® contre le chikungunya | Saint-Herblain (France), le 18 avril 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que lors de sa réunion ordinaire du 16 avril 2025, le comité consultatif américain su... |
| 16.04.2025 | Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® | Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, which will take place from April 21-24, 2025... |
| 16.04.2025 | Valneva participera à plusieurs événements lors du 25ème World Vaccine Congress dont une présentation sur son vaccin contre le chikungunya IXCHIQ® | Saint-Herblain (France), le 16 avril 2025 - Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui sa présence au 25ème World Vaccine Congress, qui se tiendra du 21 au 24 avril 2025 au ... |
| 21.10.2024 | A new step in the clinical development |
Based-based company NUCLIDIUM announced the imaging of the first patient in a Phase 1 clinical trial for its radiotracer, 61Cu-NuriPro™, aimed at diagnosing and staging prostate cancer. The phase 1 clinical trial aims at evaluating the com... |
| 13.09.2024 | Valneva Announces the Success of its Private Placement Raising approximately €60 Million | Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a... |
| 13.09.2024 | Valneva Announces the Success of its Private Placement Raising approximately €60 Million | Saint-Herblain (France), September 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces the successful pricing of its Private Placement (as defined below) for a... |
| 12.09.2024 | Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros | Saint-Herblain (France), September 12, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“Valneva” or the “Company”), a specialty vaccine company, today announces its intention to issue, subject to market conditions, approximately 22.6... |
| 08.08.2024 | New Frontiers in Vaccine Development and Cancer Treatment: A Dual Breakthrough | In the realm of healthcare, two recent developments shine like beacons of hope. LimmaTech Biologics is making strides in vaccine development, while GSK is redefining cancer treatment. Both stories reveal the relentless pursuit of innovation... |
| 08.08.2024 | The Battle Against Dementia: A New Dawn in Prevention and Awareness | Dementia looms like a shadow over millions. It’s a thief, stealing memories and identities. But recent studies shine a light on prevention. Almost half of dementia cases could be avoided. This revelation is a beacon of hope for families and... |
| 02.08.2024 | LimmaTech to receive €10 million in exclusive licensing agreement |
LimmaTech Biologics is a clinical-stage startup developing vaccines for the prevention of life-threatening diseases such as Shigellosis which is caused by Shigella bacteria. Shigellosis is the second leading cause of fatal diarrheal diseas... |
| 02.06.2024 | WHO members approve steps to bolster health regulations for pandemics | - |
| 06.03.2024 | VALNEVA Declaration of shares and voting rights - February 29, 2024 | - |
| 29.02.2024 | U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® | U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration (FDA) approval in November 20231 IXC... |
| 05.02.2024 | Valneva Announces Sale of Priority Review Voucher for $103 Million | - |
| 05.02.2024 | Valneva Announces Sale of Priority Review Voucher for $103 Million | Saint-Herblain (France), February 5, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) ... |
| 17.02.2023 | Pfizer Shuts Trial Sites for Lyme Disease Jab After Standards Breaches | Pfizer and French biotech company Valneva have removed roughly half of the participants from their Phase 3 Lyme disease vaccine trial, citing violations of ethical and scientific quality standards by a third-party operator of some of the cl... |
| 02.12.2022 | 20 years ago, a Lyme-disease vaccine was taken off the market. Now, 2 companies are developing one that could be available by 2025. | Some kinds of Borrelia bacteria, illustrated here, can cause Lyme disease. KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty Images
A Lyme-disease vaccine candidate produced antibodies that lasted at least six months.
The vaccine is being created by... |
| 21.09.2022 | Covid-19 roundup: Manufacturing contract axed for Valneva’s vaccine; Penny stock halts early infection trial | French vaccine company Valneva and German CDMO IDT Biologika have decided to terminate their manufacturing collaboration for Valneva’s Covid-19 vaccine.
IDT Biologika was originally tasked with making Valneva... |
| 13.06.2022 | Sanofi, GSK keep the ball rolling with data on second-gen Covid vaccine candidate | It isn’t likely you’ve heard a lot about ImCheck Therapeutics.
Its main base in Marseille is close to the science it’s pursuing, far from the biopharma mainstream. There are some snippets of human data, but much of the published work on the... |
| 13.06.2022 | Once promising an alternative shot, Valneva's Covid-19 supply deal with Europe on verge of collapse | When French vaccine maker Valneva signed a purchase agreement with the European Commission in November, execs touted how the deal — under which it would supply 60 million doses of its inactivated, adjuvanted whole-v... |
| 13.06.2022 | Sanofi, GSK keep the ball rolling with data on second-gen Covid vaccine candidate | Though the FDA earlier this month told Amylyx Pharmaceuticals the agency would need a little bit longer to review its ALS drug’s application, one country is forging ahead with a green light.
Canada approved Amylyx’s ALS drug AMX0035 early M... |
| 03.06.2022 | Time Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino’s CEO gig | Bruce Goldsmith
→ When Passage Bio readjusted its pipeline priorities, pruned its workforce by 13% and saw its R&D chief Eliseo Salinas walk out in March, it would be natural to assume that this confluence of events could ... |
| 14.04.2022 | Covid-19 roundup: UK authorizes 6th vaccine with Valneva's OK; FDA delays BLA for Regeneron's halted mAb combo | The UK’s drug regulator on Thursday became the first in the world to approve Valneva’s Covid-19 vaccine, which becomes the sixth Covid-19 vaccine to be granted an MHRA authorization.
The French firm’s vaccine is also the fi... |
| 25.02.2022 | Covid-19 roundup: Valneva runs into EMA questions, still expects March authorization; Canada approves first plant-based vaccine | In February 2021, the European Medicines Agency began a rolling review of French biotech Valneva’s Covid-19 vaccine, which is a whole virus, inactivated, adjuvanted vaccine.
About a year later, Valneva says the EMA still has questions, alth... |
| 24.02.2022 | Covid-19 manufacturing roundup: Scottish government invests $27M in Valneva's Covid-19 manufacturing; Moderna partners with Latin American pharma | Valneva’s Scottish unit has received a $27 million grant to fund the R&D of manufacturing its Covid-19 vaccine VLA2001.
The investment comes from the country’s economic development agency. Two grants will distribute the money over the n... |
| 09.11.2021 | The Valneva COVID-19 vaccine: Why it might be a game-changer | Since their inception and rollout, COVID-19 vaccines have changed the course of the pandemic. Prior to the vaccines, we relied on social distancing measures to help reduce the spread of the virus and a handful of imperfect treatment options... |
| 03.11.2021 | Valneva Announces Closing of Approximately $102.0 Million Global Offering | Saint-Herblain (France), November 3, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the closing which occurred on November 2, 2021 of its previously announced global offer... |
| 03.11.2021 | Valneva Announces Closing of Approximately $102.0 Million Global Offering | Saint-Herblain (France), November 3, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the closing which occurred on November 2, 2021 of its previously announced global offer... |
| 01.11.2021 | Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million | Saint-Herblain (France), November 1, 2021 – Valneva SE, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new ordinary shares, consisting of a private placement of 4,466,8... |
| 01.11.2021 | Valneva Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million - Form 6-K | Valneva Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million
Saint-Herblain (France), November 1, 2021 - Valneva SE, a specialty vaccine comp... |
| 01.11.2021 | Valneva Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to Approximately $102.0 Million | Saint-Herblain (France), November 1, 2021 – Valneva SE, a specialty vaccine company, announced today that the underwriters of its global offering of an aggregate of 4,500,000 new ordinary shares, consisting of a private placement of 4,466,8... |
| 27.10.2021 | Valneva Publishes Amendment to 2020 Universal Registration Document | Saint Herblain (France), October 27, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the publication of an amendment filed with the French Financial Markets Authority (“AMF”) on October 26... |
| 18.10.2021 | Valneva Says Its Covid Vaccine Beats AstraZeneca’s. Shares Are Surging. | American depositary receipts of Valneva jumped more than 30% Monday after the French biotech said that phase-3 trials of its Covid-19 vaccine VLA2001 had shown it triggered a stronger immune response and fewer side-effects than the shot of ... |
| 13.09.2021 | The U.K. Canceled a Vaccine Deal. Here’s the Fallout for Valneva and 3 Other Stocks. | Valneva ‘s American depositary receipt dropped almost 40% after the French company said the U.K. government had canceled a deal to buy 100 million doses of its experimental Covid-19 vaccine.
Valneva’s (ticker: VALN) ADR was down 38.5% in pr... |
| 10.08.2021 | Valneva : 2021 Half-Year Report | H1 2021
Half-Year FINANCIAL REPort
January 1 to June 30, 2021
August 10, 2021
VALNEVA SE Campus Bio-Ouest
6 rue Alain Bombard
44800 Saint-Herblain, France
www.valneva.com
VALNEVA SE H1 2021
TABLE OF CONTENTS GENERAL INTRODUCTORY COMMENTS AN... |
| 05.08.2021 | A small vaccine developer favored by the UK government in Covid-19 touts a PhIII first in chikungunya | Before Valneva garnered the favor of the UK government as a potential supplier of Covid-19 vaccines, the French biotech prided itself on being the first company to bring a chikungunya vaccine into Phase III.
It now has ... |
| 20.05.2021 | VALNEVA SE
Valneva Reports Q1 2021 Financial Results and Business Update | Excellent progress on clinical programs in the first quarter of 2021 for:
VLA15, currently the only clinical stage vaccine candidate against Lyme disease
Initiation of additional Phase 2 trial to accelerate pediatric development
VLA2001, cu... |
| 11.05.2021 | VALNEVA SE
Valneva Announces Closing of $107.6 million Global Offering | Saint-Herblain (France), May 11, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the closi... |
| 21.04.2021 | VALNEVA SE
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 | Saint-Herblain (France), April 20, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it is n... |
| 12.04.2021 | VALNEVA SE
Valneva : Announces Publication of 2020 Universal Registration Document and Provides Business Updates | Saint-Herblain France - Valneva SE ('Valneva' or the 'Company'), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announces to... |
| 15.01.2021 | NextCure hires Celgene vet as CMO; José Vega leaves Merck to become Moderna's chief safety officer | NextCure has found its new CMO after the previous executive resigned last August.
Han Myint, a biopharma and academia veteran of more than 20 years, joined the company Thursday after serving as CMO at NexImmune for a li... |
| 09.09.2020 | Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million | - |
| 10.08.2020 | VALNEVA SE
Valneva : 2020 Half-Year Report | H1 2020
Half-Year FINANCIAL REPort
January 1 to June 30, 2020
August 4, 2020
VALNEVA SE Campus Bio-Ouest
6 rue Alain Bombard
44800 Saint-Herblain, France
www.valneva.com
Table of contents GENERAL INTRODUCTORY COMMENTS AND DISCLAIMER……………………... |
| 03.02.2020 | Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed | - |
| 22.08.2019 | Can a new Lyme disease vaccine overcome a history of distrust and failure? | As the threat of Lyme disease grows and fears surrounding it spread faster than the ticks that carry the infection, researchers are developing two vaccine or vaccine-like approaches to prevent this increasingly problematic disease. But don’... |
| 25.07.2019 | ICER backs cost-effectiveness of Vascepa, Xarelto; Epizyme's lead drug wins speedy US review | → Drug cost-effectiveness watchdog ICER on Wednesday unveiled preliminary findings from its draft report on additive cardiovascular disease therapies: Amarin’s $AMRN fish oil pill Vascepa and J&J’s $JNJ blood thin... |
| - | At BIO, French delegation highlights its plans for healthcare and biotech development | At the BIO convention in San Diego June 13-16, France will have a delegation of 87 biotech and medtech companies with events punctuating each day of the conference. The French delegation is also bringing a success story about the country’s ... |
